@article{MAKHILLRJMS201610612113,
    title = {Immunohistochemical Detection of Alpha-Methyl-Co-Racemase
(AMACR) in Adenocarcinoma of Prostate},
    journal = {Research Journal of Medical Sciences},
    volume = {10},
    number = {6},
    pages = {707-710},
    year = {2016},
    issn = {1815-9346},
    doi = {rjmsci.2016.707.710},
    url = {https://makhillpublications.co/view-article.php?issn=1815-9346&doi=rjmsci.2016.707.710},
    author = {Ali,Mohammed S.,Hagir E.,Mohamed A.,Saleh A. and},
    keywords = {Prostate tumor,AMACR expression IHC,adenocarcinoma,vital factors,Saudi Arabia},
    abstract = {The aim of study was to evaluate the expression pattern of Alpha-methylacyl-CoA Racemase
(AMACR) in prostate tumors. In order to examine the relationship between AMCAR expression and tumor, we
analyzed a total of 10 cases of benign prostatic hyperplasia and 20 cases of prostate adenocarcinoma .
Expressions pattern of AMCAR were analysed and found that only one case (10%) of benign prostatic
hyperplasia showed expression whereas 19 cases (95%) of prostate adenocarcinoma showed expression at
different levels of intensity. The difference in expression pattern among benign prostatic hyperplasia and
prostate adenocarcinoma was statically significant (p>0.05). Expression profile were further categorised
according to grade of the tumor and found that AMCAR was expressed in 4 (100%), 6 (100%) and 9 (90%) in
well, moderate and poor differentiated prostate adenocarcinoma respectively. This difference of expression
among the different types of grade was statistically insignificant (p>0.05). Our results concluded that AMCAR
is a valuable diagnostic and prognostic marker of prostate cancer and one of the vital factors in pathogenesis
of prostrate adenocarcinoma.}
    }